August 2012
-
TFF Pharmaceuticals and Felix Biotechnology have signed a non-binding letter of intent for a proposed agreement regarding development of an inhaled dry powder bacteriophage for the treatment of lung infections. Felix would need to successfully… Read more . . .
-
Altimmune has signed a manufacturing agreement with Lonza for its AdCOVID intranasal vaccine candidate for the prevention of COVID-19, the companies said. In March 2020, Altimmune announced that it had partnered with the University of… Read more . . .
-
Impel NeuroPharma announced that it has submitted an NDA for its INP104 dihydroergotamine mesylate intranasal (DHE) for the treatment of migraine headaches with or without aura, which is delivered via the company’s Precision Olfactory Delivery… Read more . . .
-
Aptar has announced its acquisition of Cohero Health and all of its assets, including Cohero’s HeroTracker inhaler sensors, BreatheSmart app and platform, and mSpirometer sensors. Cohero Health CEO Joe Condurso will join Aptar Pharma. Since… Read more . . .
-
The FDA has approved Chiesi’s Bronchitol mannitol DPI for the treatment of cystic fibrosis in adult CF patients after a lengthy review process. The FDA issued a complete response letter to the original NDA in… Read more . . .
-
TFF Pharmaceuticals and Augmenta Bioworks have announced a an agreement to collaborate on development of inhaled dry powder monoclonal antibodies (mAbs) for the treatment of COVID-19 based on Augmenta’s mAbs and TFF’s thin film freezing particle… Read more . . .
-
Opiant Pharmaceuticals said that it has terminated an agreement for the use of Bespak’s Unidose Xtra device for delivery of its OPNT003 intranasal nalmefene for the treatment of opioid overdose and has entered into a… Read more . . .
-
Sorrento Therapeutics said that its intranasal Covi-Drops (STI-2099) neutralizing antibody reduced the effects of SARS-CoV-2 infection in a hamster model, and the company is planning to submit an IND for a clinical trial of Covi-Drops… Read more . . .
-
Swedish inhalation research equipment company Inhalation Sciences (ISAB) announced that it has received notification that a US patent covering the aerosol generating technology in its PreciseInhale laboratory aerosol dosing system will soon be issued. In May… Read more . . .
-
PureIMS subsidiary PIMS-E has announced that a Phase 1 clinical trial of its epinephrine DPI demonstrated that the dry powder epinephrine was well tolerated with no serious adverse reactions and produced peak plasma concentrations at… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.